Morse H G, Epperson W J, Kovaz J M, Ware J D, Barnes S M, Bleckley J E, Walker W W, Jones F G
Department of Internal Medicine, Anderson Memorial Hospital, SC.
South Med J. 1988 Jun;81(6):691-5. doi: 10.1097/00007611-198806000-00003.
To determine whether intravenous streptokinase can be delivered safely and effectively in a community hospital without acute angiography, we treated 120 patients with intravenous infusion of 1.5 million units of streptokinase shortly after arrival in the emergency room. Average time from onset of pain to treatment was 2.7 hours. Therapy was well tolerated without significant complication. Reperfusion was clinically suspected in 78% of patients. Coronary angiography was done at referral hospitals in 94% of the surviving patients two to ten days after treatment. The infarcted vessel was patent in 74% of these patients. Of these, coronary angioplasty was performed in 36%, and 32% had bypass grafting. We conclude that intravenous streptokinase can be safely and effectively used in community hospitals without acute angiography in carefully selected patients with acute myocardial infarction.
为了确定在没有急性血管造影的情况下,静脉注射链激酶能否在社区医院安全有效地使用,我们在120例患者抵达急诊室后不久,静脉输注150万单位链激酶进行治疗。从疼痛发作到治疗的平均时间为2.7小时。治疗耐受性良好,无明显并发症。78%的患者临床上怀疑有再灌注。94%的存活患者在治疗后两到十天在转诊医院进行了冠状动脉造影。这些患者中有74%的梗死血管是通畅的。其中,36%的患者进行了冠状动脉血管成形术,32%的患者进行了搭桥手术。我们得出结论,在精心挑选的急性心肌梗死患者中,在没有急性血管造影的社区医院中,静脉注射链激酶可以安全有效地使用。